REGN Long Call Strategy
REGN (Regeneron Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd.
REGN (Regeneron Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $65.20B, a trailing P/E of 14.88, a beta of 0.24 versus the broader market, a 52-week range of 518.9-821.11, average daily share volume of 964K, a public-listing history dating back to 1991, approximately 15K full-time employees. These structural characteristics shape how REGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.24 indicates REGN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. REGN pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a long call on REGN?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current REGN snapshot
As of June 29, 2026, spot at $633.31, ATM IV 35.12%, IV rank 39.37%, expected move 10.07%. The long call on REGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 32-day expiry.
Why this long call structure on REGN specifically: REGN IV at 35.12% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 10.07% (roughly $63.77 on the underlying). The 32-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated REGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on REGN should anchor to the underlying notional of $633.31 per share and to the trader's directional view on REGN stock.
REGN long call setup
The REGN long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With REGN near $633.31, the first option leg uses a $630.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed REGN chain at a 32-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 REGN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $630.00 | $28.80 |
REGN long call risk and reward
- Net Premium / Debit
- -$2,880.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$2,880.00
- Breakeven(s)
- $658.80
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
REGN long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on REGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$2,880.00 |
| $140.04 | -77.9% | -$2,880.00 |
| $280.06 | -55.8% | -$2,880.00 |
| $420.09 | -33.7% | -$2,880.00 |
| $560.12 | -11.6% | -$2,880.00 |
| $700.15 | +10.6% | +$4,134.62 |
| $840.17 | +32.7% | +$18,137.34 |
| $980.20 | +54.8% | +$32,140.07 |
| $1,120.23 | +76.9% | +$46,142.79 |
| $1,260.26 | +99.0% | +$60,145.51 |
When traders use long call on REGN
Long calls on REGN express a bullish thesis with defined risk; traders use them ahead of REGN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
REGN thesis for this long call
The market-implied 1-standard-deviation range for REGN extends from approximately $569.54 on the downside to $697.08 on the upside. A REGN long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current REGN IV rank near 39.37% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on REGN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, REGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to REGN-specific events.
REGN long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. REGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move REGN alongside the broader basket even when REGN-specific fundamentals are unchanged. Long-premium structures like a long call on REGN are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current REGN chain quotes before placing a trade.
Frequently asked questions
- What is a long call on REGN?
- A long call on REGN is the long call strategy applied to REGN (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With REGN stock trading near $633.31, the strikes shown on this page are snapped to the nearest listed REGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are REGN long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the REGN long call priced from the end-of-day chain at a 30-day expiry (ATM IV 35.12%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,880.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a REGN long call?
- The breakeven for the REGN long call priced on this page is roughly $658.80 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current REGN market-implied 1-standard-deviation expected move is approximately 10.07%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on REGN?
- Long calls on REGN express a bullish thesis with defined risk; traders use them ahead of REGN catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current REGN implied volatility affect this long call?
- REGN ATM IV is at 35.12% with IV rank near 39.37%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.